D
IPR000536

Nuclear hormone receptor, ligand-binding domain

InterPro entry
Short nameNucl_hrmn_rcpt_lig-bd
Overlapping
homologous
superfamilies
 
domain relationships

Description

Nuclear receptors (NRs), such as the receptors for steroids and thyroid hormones, retinoids and vitamin D3, are one of the most abundant classes of transcriptional regulators in animals (metazoans). They regulate diverse functions, such as homeostasis, reproduction, development and metabolism. The most prominent feature differentiating them from other transcription factors is their capacity to bind small hydrophobic molecules specifically. These ligands constitute regulatory signals, which modify the NR transcriptional activity through conformational changes. Prototypical NRs share a common structural organisation with a variable N-terminal domain that contains a constitutively active activation function (AF)-1, a conserved DNA- binding domain (DBD) consisting of two zinc fingers, a linker region, and a C-terminal ligand-binding domain (LBD), also called HOLI domain
[5, 3, 4]
.

The NR LBD plays a crucial role in ligand-mediated NR activity. In addition to its role is ligand recognition, the LBD also contains a ligand-dependent AF-2. Conformational changes in AF-2 induced by various ligands can modulate interactions with conserved motifs of coregulatory proteins. Specifically, the binding of ligands to the LBD determines the recruiting of transcriptional coregulators which triggers induction or repression of target genes. The coregulators include coactivators like the p160 factors also referred to as the steroid receptor coactivators (SRC) family, and corepressors such as SMART (silencing mediator for retinoid and thyroid hormone receptors) and N-CoR (nuclear corepressor)
[6, 7, 1, 2]
.

The overall structure of NR LBD is composed of about 11-13 α-helices that are arranged into a three-layer antiparallel α-helical sandwich with the three long helices (helices 3, 7, and 10) forming the two outer layers. The middle layer of helices (helices 4, 5, 8 and 9) is present only in the top half of the domain but is missing from the bottom half, thereby creating a cavity, so called ligand-binding pocket, for ligand binding in most receptors. The bound ligands stabilize the NR conformation through direct contacts with multiple structural elements including helices H3, H5, H6, H7, H10, and the loop proceeding the AF-2 helix. The C-terminal activation region also forms an α-helix (AF-2), which can adopt multiple conformation depending on the nature of the bound ligand. Helices 3,4 and 12 enclose a shallow hydrophobic groove which is the site for coregulator binding. Despite the conserved fold of NR LBDs, the ligand-binding pocket is the least conserved region among different NR LBDs
[7, 1, 2]
.

References

1.The nuclear receptor ligand-binding domain: structure and function. Moras D, Gronemeyer H. Curr. Opin. Cell Biol. 10, 384-91, (1998). View articlePMID: 9640540

2.Structural and functional insights into nuclear receptor signaling. Jin L, Li Y. Adv. Drug Deliv. Rev. 62, 1218-26, (2010). View articlePMID: 20723571

3.Signature of the oligomeric behaviour of nuclear receptors at the sequence and structural level. Brelivet Y, Kammerer S, Rochel N, Poch O, Moras D. EMBO Rep. 5, 423-9, (2004). View articlePMID: 15105832

4.Molecular cloning and tissue distribution of peroxisome proliferator-activated receptor-alpha (PPARα) and gamma (PPARγ) in the pigeon (Columba livia domestica). Xie P, Yuan C, Wang C, Zou XT, Po Z, Tong HB, Zou JM. Br. Poult. Sci. 55, 136-42, (2014). View articlePMID: 24844133

5.The nuclear receptor superfamily. Robinson-Rechavi M, Escriva Garcia H, Laudet V. J. Cell. Sci. 116, 585-6, (2003). View articlePMID: 12538758

6.Local motifs involved in the canonical structure of the ligand-binding domain in the nuclear receptor superfamily. Tsuji M. J. Struct. Biol. 185, 355-65, (2014). View articlePMID: 24361687

7.Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Bourguet W, Germain P, Gronemeyer H. Trends Pharmacol. Sci. 21, 381-8, (2000). View articlePMID: 11050318

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our Privacy Notice and Terms of Use.